UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000006337 |
|---|---|
| Receipt number | R000007514 |
| Scientific Title | Variability of response to anti-thrombotic drug - Analysis of profile of coagulation and fibrinolysis in patients receiving total hip replacement (THR) |
| Date of disclosure of the study information | 2011/09/13 |
| Last modified on | 2019/03/26 15:44:17 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Variability of response to anti-thrombotic drug - Analysis of profile of coagulation and fibrinolysis in patients receiving total hip replacement (THR)
Acronym
Variability of response to anti-thrombotic drug - prof ile of coagulation and fibrinolysis in patients receiving THR
Scientific Title
Variability of response to anti-thrombotic drug - Analysis of profile of coagulation and fibrinolysis in patients receiving total hip replacement (THR)
Scientific Title:Acronym
Variability of response to anti-thrombotic drug - prof ile of coagulation and fibrinolysis in patients receiving THR
Region
| Japan |
Condition
Condition
osteoarthritis of the hip, hip fracture
Classification by specialty
| Orthopedics |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
To clarify the duration of hypercoagulable state post THR
Basic objectives2
Others
Basic objectives -Others
plasma concentrations of coagulation and fibrinolysis markers
Trial characteristics_1
Exploratory
Trial characteristics_2
Pragmatic
Developmental phase
Not applicable
Assessment
Primary outcomes
plasma concentrations of markers of coagulation and fibrinolysis at the time-point of three weeks after THR
Key secondary outcomes
occurrence of symptomatic VTE, clinically proven bleeding symptom (TIMI major or minor), plasma concentrations of markers of coagulation and fibrinolysis at the time-point of first visiting after discharge
Base
Study type
Observational
Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| Not applicable |
Age-upper limit
| Not applicable |
Gender
Male and Female
Key inclusion criteria
patients receiving THR and anticoagulants post THR for VTE prevention
Key exclusion criteria
1) patients without consent
2) AST > or = 3 x upper limit or ALT > or = 3 x upper
3) serum CRTNN > 2 mg/dl
4) Hb = or < 10 g/dl, or platelet = or < 100k
5) drug allergy to anticoagulants
6) patients with malignancy under treatment or planning to start treatment within one year
7) primary physician thinks it is inappropriate to enroll the patient
Target sample size
100
Research contact person
Name of lead principal investigator
| 1st name | |
| Middle name | |
| Last name | Mitsuru Murata |
Organization
Keio University School of Medicine
Division name
Department of Laboratory Medicine
Zip code
Address
35 Shinano-machi Shinjuku-ku Tokyo 160-8582, Japan
TEL
81-3-3353-1211
Public contact
Name of contact person
| 1st name | |
| Middle name | |
| Last name | Kenji Yokoyama |
Organization
Keio University, School of Meidicine
Division name
Division of Hematology, Department of Medicine
Zip code
Address
35 Shinano-machi Shinjuku-ku Tokyo 160-8582, Japan
TEL
03-3353-1211
Homepage URL
keyokoya@sc.itc.keio.ac.jp
Sponsor or person
Institute
Keio University, School of Medicine, Research Park 5S9
Institute
Department
Personal name
Funding Source
Organization
DAIICHI SANKYO COMPANY LIMITED
Organization
Division
Category of Funding Organization
Profit organization
Nationality of Funding Organization
JAPAN
Other related organizations
Co-sponsor
Department of Orthopedic surgery, Saiseikai Central Hospital
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Address
Tel
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
東京都済生会中央病院（東京都）
Other administrative information
Date of disclosure of the study information
| 2011 | Year | 09 | Month | 13 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Completed
Date of protocol fixation
| 2010 | Year | 10 | Month | 01 | Day |
Date of IRB
| 2010 | Year | 10 | Month | 01 | Day |
Anticipated trial start date
| 2010 | Year | 10 | Month | 01 | Day |
Last follow-up date
| 2013 | Year | 12 | Month | 31 | Day |
Date of closure to data entry
| 2013 | Year | 12 | Month | 31 | Day |
Date trial data considered complete
| 2013 | Year | 12 | Month | 31 | Day |
Date analysis concluded
| 2013 | Year | 12 | Month | 31 | Day |
Other
Other related information
primary endopoint
plasma concentrations of markers of coagulation and fibrinolysis at the time-point of three weeks after THR
secondary endopoint
occurrence of symptomatic VTE, clinically proven bleeding symptom (TIMI major or minor), plasma concentrations of markers of coagulation and fibrinolysis at the time-point of first visiting after discharge
Management information
Registered date
| 2011 | Year | 09 | Month | 12 | Day |
Last modified on
| 2019 | Year | 03 | Month | 26 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000007514
